Literature DB >> 21471258

Randomized controlled trial of bilateral intrapleural block in cardiac surgery.

Mojtaba Mansouri1, Keivan Bageri, Esmaiel Noormohammadi, Mohsen Mirmohammadsadegi, Abolgasem Mirdehgan, Atefeh Gholami Ahangaran.   

Abstract

The aim of this study was to determine the efficacy of bilateral intrapleural block with bupivacaine as a preemptive analgesic for postoperative pain in coronary artery bypass graft surgery. In a double-blind prospective clinical trial, 70 patients were randomly divided into a bupivacaine group (20 mL bupivacaine 0.25% and 0.5 mL adrenaline 1/200,000 each side) and a control group (20.5 mL normal saline each side). Evaluation of the severity of pain was performed using the visual analog scale at 12 and 24 h after entering the intensive care unit and again during chest tube removal. Pain scores at 12 and 24 h after intensive care unit admission were significantly lower in the bupivacaine group. There were no side-effects related to intrapleural block, such as pneumothorax or emphysema. In coronary artery bypass graft candidates, preemptive analgesia with bilateral intrapleural block using bupivacaine provided relatively less painful conditions during the first 24 h after surgery, but it did not improve the clinical outcome.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21471258     DOI: 10.1177/0218492311400921

Source DB:  PubMed          Journal:  Asian Cardiovasc Thorac Ann        ISSN: 0218-4923


  2 in total

Review 1.  Postthoracotomy Ipsilateral Shoulder Pain: A Literature Review on Characteristics and Treatment.

Authors:  Fardin Yousefshahi; Oana Predescu; Melissa Colizza; Juan Francisco Asenjo
Journal:  Pain Res Manag       Date:  2016-11-28       Impact factor: 3.037

2.  The effect of bilateral intrapleural infusion of lidocaine with fentanyl versus only lidocaine in relieving pain after coronary artery bypasses surgery.

Authors:  Kamran Shadvar; Sarvin Sanaie; Ata Mahmoodpoor; Mitra Safarpoor; Bahman Nagipour
Journal:  Pak J Med Sci       Date:  2017 Jan-Feb       Impact factor: 1.088

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.